New Device Promises Better Pain Readings in Surgery
Published Date: 6/1/2026
Rule
Summary
The FDA is officially putting the adjunctive pain measurement device for anesthesiology into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while making it easier for patients to get new, helpful technology. The new classification is effective June 1, 2026, and could speed up innovation without extra costs for makers.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
New Special Controls Require Validation
Manufacturers must meet specific special controls before marketing: provide clinical data validating algorithms (including accuracy vs a reference, data representativeness, evaluation of pain types, and separate validation datasets for machine-learning algorithms), perform software verification/validation and hazard analysis, non-clinical performance testing for signal quality, usability assessment, biocompatibility testing, and electrical/electromagnetic safety testing.
Adjunctive Pain Device Moved to Class II
The FDA classified the adjunctive pain measurement device for anesthesiology as Class II (special controls), effective June 1, 2026 (classification was applicable February 17, 2023). The device is subject to premarket notification (510(k)) and can serve as a predicate for future devices, which the FDA says reduces regulatory burdens and can speed innovation without imposing extra costs on makers.
Labeling Must Show Clinical Demographics
Labeling for these devices must include a summary of clinical validation data with participant demographics (age, sex, race or ethnicity, patient condition), anesthetic regimen (types and doses), summary of results, information on subpopulations that may have disparate performance, a description of what the device measures and outputs, compatible sensor types, warnings about sensor and patient-condition limitations, and recommendations emphasizing adjunctive use.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10898 — Medical Devices; Hematology and Pathology Devices; Classification of the Von Willebrand Factor Assay
The FDA is officially putting the von Willebrand factor assay into Class II, meaning it now has special safety rules but fewer red tape hurdles. This change helps labs and patients get access to this important blood test faster and safer, starting June 1, 2026. If you make or use these devices, expect smoother approvals and no big cost jumps.
2026-10904 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Orally Ingested Transient Device for Constipation
The FDA is officially putting the new swallowed device for constipation into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this cool innovation by cutting down red tape. The new rules took effect June 1, 2026, and could save companies time and money getting their devices approved.
2026-10907 — Medical Devices; Anesthesiology Devices; Classification of the Real-Time Ultrasound Anatomy Visualization and Labeling Device for Ultrasound Guided Regional Anesthesia
The FDA is officially classifying a new ultrasound device that helps doctors see and label anatomy in real-time during regional anesthesia as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change makes it easier and faster for patients to get access to this helpful technology without compromising safety. The new classification is effective June 1, 2026, and could save time and money for device makers and hospitals.
2026-10899 — Medical Devices; Dental Devices; Classification of the Intraoral Cooling Device
The FDA is officially putting the intraoral cooling device into class II, meaning it has special safety rules but fewer hurdles than the highest-risk devices. This change helps make sure the device is safe and effective while making it easier for patients to get this cool tech. The new classification is effective June 1, 2026, but it’s been in place since October 14, 2022, so manufacturers can plan ahead without extra costs.
2026-10894 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Oropharyngeal Electrical Stimulator
The FDA is officially putting the oropharyngeal electrical stimulator into Class II, meaning it has special safety rules but is easier to get to patients. This change helps make sure the device is safe and effective while cutting down on red tape, so more people can benefit from this cool tech. The new rules took effect on June 1, 2026, but the classification has been in place since September 2022.
2026-10908 — Medical Devices; General Hospital and Personal Use Devices; Classification of the Rigid Sterilization Container With Electronic Monitoring
The FDA is officially classifying rigid sterilization containers with electronic monitoring as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change helps hospitals and medical device makers get these safer, smarter containers to patients faster and easier. The new rules took effect June 1, 2026, making it simpler and potentially less costly to bring these devices to market.
Previous / Next Documents
Previous: 2026-10904 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Orally Ingested Transient Device for Constipation
The FDA is officially putting the new swallowed device for constipation into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this cool innovation by cutting down red tape. The new rules took effect June 1, 2026, and could save companies time and money getting their devices approved.
Next: 2026-10907 — Medical Devices; Anesthesiology Devices; Classification of the Real-Time Ultrasound Anatomy Visualization and Labeling Device for Ultrasound Guided Regional Anesthesia
The FDA is officially classifying a new ultrasound device that helps doctors see and label anatomy in real-time during regional anesthesia as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change makes it easier and faster for patients to get access to this helpful technology without compromising safety. The new classification is effective June 1, 2026, and could save time and money for device makers and hospitals.